The Sidney Kimmel Foundation for Cancer Research Seeks 1998 Scholar Applicants

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

The Sidney Kimmel Foundation for Cancer Research is seeking accomplished young investigators to apply for Kimmel Scholar Awards. The Kimmel Scholar Award, established in 1997, will be presented every year to up to 10 investigators who

The Sidney Kimmel Foundation for Cancer Research is seeking accomplished young investigators to apply for Kimmel Scholar Awards. The Kimmel Scholar Award, established in 1997, will be presented every year to up to 10 investigators who demonstrate creative approaches to cancer research with an emphasis on basic and translational cancer research and clinical research with novel or innovative treatment strategies.

The grant recipients will be selected by a Medical Advisory Board consisting of distinguished cancer researchers who represent a wide array of cancer research interests, including, but not limited to, pharmacology, surgery, pediatrics, radiation biology, immunology, and cancer prevention.

The Medical Advisory Board will select up to 10 grant recipients who will receive $100,000 each per year for 2 years. Qualified applicants must hold an md, phd, or equivalent graduate degree and must perform research in an American not-for-profit institution during the period of Kimmel Foundation support.

Investigators interested in receiving an application to become a Kimmel Scholar may contact Dr. Gary Cohen, director of the Sidney Kimmel Foundation, via facsimile request at (410) 512-8789. Completed applications must be received by the Foundation no later than December 19, 1997.

“I am very pleased to have the opportunity to support the most promising and accomplished young investigators in this country who have dedicated their careers to prevent and treat individuals with cancer,” said Sidney Kimmel. “Each one of us has either personally, or through a loved one or friend, been exposed to cancer. We are determined to make a significant contribution to the fight against cancer. That is why for the second consecutive year, The Sidney Kimmel Foundation for Cancer Research is donating $1 million towards research that may one day result in a cure for all forms of cancer and cancer-related diseases.”

The Sidney Kimmel Foundation for Cancer Research, founded by Sidney Kimmel, founder and chairman of Jones Apparel Group, is a division of The Sidney Kimmel Foundation, which has committed nearly $50 million to a variety of charitable causes since its establishment in 1993.

The Medical Advisory Board consists of the following members: Joseph Bertino, MD, Memorial Sloan-Kettering Cancer Center; Webster Cavenee,PhD, Ludwig Institute, University of California; Curt Civin, MD, Johns Hopkins Oncology Center; Carlo Croce, MD, Kimmel Cancer Center of Jefferson Medical College; Judah Folkman, MD, Harvard Medical School; Samuel Hellman,MD, University of Chicago; Waun Ki Hong, MD, UT M. D. Anderson Cancer Center; Mary Claire King, PhD, University of Washington; Steven A. Rosenberg, MD, PhD, National Cancer Institute; and Ivor Royston, MD, Sidney Kimmel Cancer Center. The Board of Directors consist of Sidney Kimmel, Chairman; Richard Butera, President; Richard Jaffe, Esq; and Dr. Gary Cohen, Administrative Director.

Recent Videos
Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.
James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
A panel of 5 experts on multiple myeloma